LENSAR, Inc. (LNSR)
| Market Cap | 65.07M |
| Revenue (ttm) | 58.44M |
| Net Income (ttm) | -34.28M |
| Shares Out | 12.10M |
| EPS (ttm) | -2.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,464 |
| Open | 5.21 |
| Previous Close | 5.21 |
| Day's Range | 5.21 - 5.46 |
| 52-Week Range | 5.06 - 14.31 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+85.87%) |
| Earnings Date | May 11, 2026 |
About LNSR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic... [Read more]
Financial Performance
In 2025, LENSAR's revenue was $58.44 million, an increase of 9.24% compared to the previous year's $53.49 million. Losses were -$34.28 million, 9.16% more than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for LNSR stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
LENSAR Earnings Call Transcript: Q4 2025
2025 saw strong recurring revenue and procedure growth despite acquisition-related disruptions, with LENSAR regaining independence and focusing on expanding its installed base and international reach. Gross margins remained healthy, and positive adjusted EBITDA was achieved.
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review
In March 2025, Alcon agreed to acquire the laser solutions company for $14.00 per share for an aggregate implied value of approximately $356 million.
LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treat...
LENSAR® Provides Update on Pending Acquisition by Alcon
ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...
LENSAR® Reports Third Quarter 2025 Results and Provides Business Update
18 ALLY Robotic Cataract Laser Systems ® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser insta...
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors gran...
LENSAR Reports Second Quarter 2025 Results and Provides Business Update
18 ALLY Robotic Cataract Laser Systems™ (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...
LENSAR Reports First Quarter 2025 Results and Provides Business Update
14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025
LENSAR Earnings Call Transcript: Q4 2024
Record revenue and system placements in 2024 drove 27% annual growth, with recurring revenue exceeding $40 million and strong U.S. and international expansion. Positive adjusted EBITDA was achieved, and 2025 guidance calls for even higher revenue growth and continued market share gains.
LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385...
LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025
ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...
LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day
ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...
LENSAR Earnings Call Transcript: Q3 2024
Record Q3 with 38% revenue growth and 24 new ALLY system placements, driven by international expansion and strong recurring revenue. U.S. procedure market share rose to 20%, with Q4 and 2025 growth expected as recent installations ramp up.
LENSAR Reports Third Quarter 2024 Results and Provides Business Update
24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024
LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...
One Millionth Procedure Completed Using LENSAR's Cataract Laser Systems
ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...
LENSAR Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024
ALLY's advanced imaging and AI-driven laser system is transforming cataract surgery, delivering superior clinical outcomes, significant cost savings, and increased revenues for surgical centers and surgeons. Rapid U.S. market share gains and international expansion signal strong growth potential.
LENSAR to Participate in Two Upcoming Investor Conferences
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today ...
LENSAR Earnings Call Transcript: Q2 2024
Record Q2 with 17 ALLY placements and $12.6M revenue, up 5% year-over-year, driven by strong U.S. and global procedure growth. EU and Taiwan clearances enable international expansion, with robust backlog and positive adjusted EBITDA.
LENSAR Reports Second Quarter 2024 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today ...
LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today a...
LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today a...